Live Chat

Trade Vir Biotechnology VIR

VirBiotechnology live chart

Instrument Fundamentals

Weekly Search
Weekly
Daily
Date Close Change Change (%) Open High Low

News

Webhose 2024 Dec 02, 21:50

Vir Biotechnology Trades Higher in Sympathy with Janux Therapeutics By Investing.com

Vir Biotechnology Inc
Webhose 2024 Nov 29, 08:11

Victory Capital Management Inc. Acquires 15,696 Shares of Vir Biotechnology, Inc. (NASDAQ:VIR)

Vir Biotechnology Inc
Webhose 2024 Nov 26, 14:30

Vir Biotechnology to Host Virtual Investor Event on PRO-XTEN™ Masked T-Cell Engager Programs | Morningstar

Vir Biotechnology Inc
Webhose 2024 Nov 25, 14:30

Company Website: https://www.vir.bio SAN FRANCISCO -- (Bus

Vir Biotechnology Inc
Webhose 2024 Nov 25, 14:26

Vir Biotechnology's SWOT analysis: stock poised for growth amid clinical progress By Investing.com

Vir Biotechnology Inc
Webhose 2024 Nov 24, 08:52

HC Wainwright Reiterates Buy Rating for Vir Biotechnology (NASDAQ:VIR)

Vir Biotechnology Inc
Webhose 2024 Nov 24, 06:54

Head-To-Head Survey: Coherus BioSciences (NASDAQ:CHRS) vs. Vir Biotechnology (NASDAQ:VIR)

Vir Biotechnology Inc
Webhose 2024 Nov 20, 15:30

Vir Biotechnology poised for outperformance, keeps buy rating on pipeline potential By Investing.com

Vir Biotechnology Inc
Webhose 2024 Nov 20, 13:11

Needham & Company LLC Reaffirms Buy Rating for Vir Biotechnology (NASDAQ:VIR)

Vir Biotechnology Inc
Webhose 2024 Nov 20, 09:00

Empowered Funds LLC Decreases Stake in Vir Biotechnology, Inc. (NASDAQ:VIR)

Vir Biotechnology Inc
Webhose 2024 Nov 19, 02:15

Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program | Morningstar

Vir Biotechnology Inc
Webhose 2024 Nov 18, 18:20

Vir Biotechnology Presents Positive Chronic Hepatitis Delta Clinical Trial Data and Announces Initiation of Phase 3 Registrational Program By Investing.com

Vir Biotechnology Inc
Webhose 2024 Nov 18, 13:10

Vir Biotechnology Receives Positive Opinion on Orphan Drug Designation for Tobevibart and Elebsiran in Chronic Hepatitis Delta from European Medicines Agency By Investing.com

Vir Biotechnology Inc
Webhose 2024 Nov 18, 10:54

Vir Biotechnology stock hits 52-week low at $7.08 By Investing.com

Vir Biotechnology Inc
Webhose 2024 Nov 17, 14:35

Vir Biotechnology: Promising Hepatitis B Treatment Data Amid Cautious Optimism and Awaited Milestones

Vir Biotechnology Inc
Webhose 2024 Nov 13, 11:03

Vir Biotechnology, Inc. (NASDAQ:VIR) Shares Sold by Baillie Gifford & Co.

Vir Biotechnology Inc

Latest news

Frances Wang 2024 Dec 10, 16:00

Asian stock markets today: Asian Shares Rise as Chinese Stocks Soar

Stocks
Frances Wang 2024 Dec 10, 16:00

Gold Prices Surge Amid Geopolitical Tensions and Fed Rate Speculations

Commodities
Frances Wang 2024 Dec 09, 16:00

NASDAQ IBIT: how high will iShares Bitcoin Trust ETF go?

Cryptocurrencies ETFs
Frances Wang 2024 Dec 09, 16:00

What stocks will boom in 2025: Nasdaq potential stock analysis

Stocks
Frances Wang 2024 Dec 09, 16:00

Bitcoin over $100K: will bitcoin ETFs surge too?

Cryptocurrencies
EURUSD challenges
Dyogenes Diniz 2024 Dec 08, 17:00

Morning Note: US and Europe: PMI Data, Index Trends, and EURUSD Analysis

EUR USD S&P 500
Frances Wang 2024 Dec 08, 16:00

Fed rate cut probability in December rises: Bitcoin Reacts to U.S. Jobs Data

Cryptocurrencies
Dyogenes Diniz 2024 Dec 05, 16:00

Week ahead: Inflation and Interest rates to shake the Markets this week

Indices Forex

Info

Spread

0.05

Spread (%)

0.6180 %

Leverage

1:10

Overnight Interest Buy

-0.0597 %

Overnight Interest Sell

-0.0292 %

Currency

USD

Trading Hours

Markets closed

Wednesday

14:31 - 20:59

Monday

14:31-20:59

Tuesday

14:31-20:59

Thursday

14:31-20:59

Friday

14:31-20:59

Analysis and statistics

Open

---

Previous Close

---

52 Week High/Low

--- – ---

Market cap

1200918400

Shares Outstanding

137720000

Earnings Date (Next)

0000-00-00

Div Yield

Ex-Dividend Date

Forward annual dividend rate

0

Forward annual dividend yield

0

EPS

-3.93

Learn more about this instrument

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Related Instruments

Asset
Sell
Buy
Change (%)
View all instruments
Trustpilot
Live Chat